Not Yet RecruitingNot Applicable

Anesthesia Comparison in Early-stage Small NSCLC: A Multicenter RCT

410 participantsStarted 2026-03-15

Plain-language summary

This study is a prospective, randomized, controlled study, which intends to enroll patients with suspected early-stage NSCLC (non-small cell lung cancer) with a diameter of ≤ 3 cm as research subjects. The study is conducted in accordance with the Declaration of Helsinki. It has been approved by the Ethics Committee of the Second Affiliated Hospital of Air Force Medical University, and patients or their family members have signed the informed consent form. Patients undergoing VATS (video-assisted thoracic surgery) are enrolled in the Department of Thoracic Surgery of the Second Affiliated Hospital of Air Force Medical University. The patients are randomly divided into two groups: the NIVATS (non-intubated video-assisted thoracic surgery) group and the OLV (one-lung ventilation) group. By observing various perioperative indicators of the patients, the short-term efficacy of the two techniques in patients with early-stage NSCLC is compared, so as to evaluate the safety and effectiveness of the NIVATS surgical treatment method.

Who can participate

Age range

75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≤ 75 years; * Gender is not limited; * Patients with suspected T1 stage non-small cell lung cancer (NSCLC) in preoperative clinical staging, with thin-slice CT showing that the maximum tumor diameter is ≤ 3.0 cm, single or multiple nodules, and the nodules requiring surgical resection are located in the same ipsilateral lung lobe, with the number of nodules resected simultaneously ≤ 3; * American Society of Anesthesiologists (ASA) classification ≤ Grade III (preferably Grade I - II is recommended); * Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1; * Body Mass Index (BMI) \< 25 kg·m-²; * Normal cardiopulmonary function: predicted forced expiratory volume in the first second (FEV1%) \> 50%, resting blood gas analysis showing arterial oxygen partial pressure (PaO2) ≥ 75 mmHg, arterial carbon dioxide partial pressure (PaCO2) \< 45 mmHg; ejection fraction (EF) \> 50%, 6-minute walk distance (6MWD) ≥ 350 m; * No severe upper airway lesions, Mallampati classification I - II; * No contraindications related to paravertebral nerve block and intercostal nerve block; * Estimated surgical time ≤ 150 minutes; * Patients have no history of clinically significant cardiac or neurological problems. Exclusion Criteria: * A history of ipsilateral lung surgery; * Interstitial pneumonia, pulmonary fibrosis, severe emphysema, severe chronic obstructive pulmonary disease, acute phase of pulmonary infection, or uncontrolled asthma; * Sleep apnea syndro…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Average postoperative hospital stay

Timeframe: up to 3 months

Intraoperative opioid consumption

Timeframe: 1 day

Trial details

NCT IDNCT07327736

SponsorTang-Du Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-06-30

Contact for this trial

Xiaolong Yan, Doctor of Medicine (M.D.)

+8615991269383 yanxiaolong@fmmu.edu.cn

View on ClinicalTrials.gov More Patients With Suspected Non-small Cell Lung Cancer (NSCLC) at Clinical Stage T1 trials